Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Increased by Natixis Advisors L.P.

Natixis Advisors L.P. raised its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 33.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 258,736 shares of the medical equipment provider's stock after buying an additional 64,968 shares during the quarter. Natixis Advisors L.P. owned about 0.11% of Hologic worth $18,486,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Nordea Investment Management AB increased its holdings in Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider's stock worth $113,077,000 after buying an additional 69,494 shares during the period. Louisiana State Employees Retirement System acquired a new position in Hologic in the 4th quarter worth approximately $1,057,000. Pathstone Family Office LLC grew its stake in shares of Hologic by 96.0% during the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider's stock worth $643,000 after purchasing an additional 4,542 shares during the period. Ontario Teachers Pension Plan Board grew its stake in shares of Hologic by 186.7% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider's stock worth $2,665,000 after purchasing an additional 25,010 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Hologic by 145.3% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider's stock worth $56,000 after purchasing an additional 468 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. UBS Group raised their price objective on shares of Hologic from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, February 2nd. JPMorgan Chase & Co. increased their target price on Hologic from $85.00 to $91.00 and gave the company an "overweight" rating in a research report on Friday. Needham & Company LLC restated a "buy" rating and issued a $90.00 price objective on shares of Hologic in a report on Friday. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Finally, Evercore ISI raised their price objective on Hologic from $76.00 to $78.00 and gave the company an "in-line" rating in a report on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $84.56.

Insider Buying and Selling at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company's stock, valued at approximately $119,802.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Scott T. Garrett sold 16,441 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares of the company's stock, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now owns 1,572 shares of the company's stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

Hologic Trading Down 0.8 %

Shares of NASDAQ:HOLX traded down $0.61 during midday trading on Monday, reaching $75.93. 1,585,120 shares of the company's stock were exchanged, compared to its average volume of 1,752,628. The firm's 50 day simple moving average is $76.13 and its two-hundred day simple moving average is $73.09. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. The stock has a market cap of $17.82 billion, a price-to-earnings ratio of 39.05, a P/E/G ratio of 2.55 and a beta of 1.01. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $86.74.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company's quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the company earned $1.06 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.